BD MAX™ Enteric Parasite Panel Receives FDA Clearance for Detection of Common and Pathogenic Intestinal Parasites
"What we see as the value it will bring to us is the speed with which we can accurately provide patient results," said
Globally, there are approximately 1.7 billion cases of diarrhea accounting for more than 2 million deaths annually. Children less than 5 years of age are particularly at risk with around 760,000 deaths each year.ii These infections may be caused by viruses, bacteria or parasites and often take two to three days or more to identify in the clinical laboratory using conventional methods. Infections caused by the parasites Giardia and Cryptosporidia, while relatively common, may be subject to under-diagnosis and reporting in the US.iii
"The BD MAX assays for Clostridium difficile (C. diff) and selected enteric bacterial and parasitic pathogens are the first commercial assays for selective, targeted diagnosis of enteric infectious diseases, an approach that is consistent with the recommendations of the
In the laboratory, the BD MAX System automates sample preparation, extraction, amplification and detection on a single system, saving time and improving lab efficiency. Molecular testing on the BD MAX System is simplified and standardized, to minimize variability in results.
The BD MAX menu includes syndromic panels for Healthcare Associated Infections, Reproductive & Sexually Transmitted Infections and Enteric Pathogens, enabling lab professionals in their efforts to deliver diagnostic results that improve lab operations.
BD is a leading medical technology company that partners with customers and stakeholders to address many of the world's most pressing and evolving health needs. Our innovative solutions are focused on improving medication management and patient safety; supporting infection prevention practices; equipping surgical and interventional procedures; improving drug delivery; aiding anesthesiology and respiratory care; advancing cellular research and applications; enhancing the diagnosis of infectious diseases and cancers; and supporting the management of diabetes. We are more than 45,000 associates in 50 countries who strive to fulfill our purpose of "Helping all people live healthy lives" by advancing the quality, accessibility, safety and affordability of health care around the world. In 2015, BD welcomed CareFusion and its products into the BD family of solutions. For more information on BD, please visit www.bd.com.
i MMWR, CDC,
ii WHO Fact Sheet,
iv Manual of Clinical Microbiology, 11th ed., ch.18, 2015
v Guerrant RL et al., Practice Guidelines for the Management of Infectious Disease, Clin Infect Dis,2001.
BD Public Relations
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bd-max-enteric-parasite-panel-receives-fda-clearance-for-detection-of-common-and-pathogenic-intestinal-parasites-300147966.html
SOURCE BD (